TrialAmerican journal of clinical dermatology2026

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.

Andrew F Alexis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.